Table 2.
Characteristics of eyes of patients who underwent amniotic membrane transplantation or ProKera device implantation in the acute phase of Stevens-Johnson syndrome/toxic epidermal necrolysis
| Category | Patients with AM in the acute phase of SJS/TEN; n=55 eyes (%) |
|---|---|
| BCVA at onset of SJS/TEN | |
| ≥ 20/40 | 45 (82) |
| Could not be measured | 10 (l8) |
| Number of eyes in acute phase with, n (%) | |
| Conjunctival hyperemia | 55 (100) |
| Lid margin involvement (denudation of epithelium) | 47 (85) |
| Conjunctival pseudomembranes | 22 (40) |
| Conjunctival epithelial defects | 44 (80) |
| Corneal epithelial defects | 31 (56) |
| Number of eyes in acute phase with, n (%)* | |
| Grade 2 involvement | 34 (62) |
| Grade 3 involvement | 21 (38) |
| Number of eyes which received AM at | |
| Bedside | 45 (82) |
| Operating room | 10 (18) |
| Median period at which AM was received from the onset of skin rash (IQR) | 5 days (3–7) |
| Median time to dissolution of AM (IQR) | 9 days (7–9) |
| Number of eyes with primary AMT which required | |
| Repeat AM in the form of AMT | 3/31 (10) |
| Repeat AM in the form of PD | 15/31 (48) |
| Number of eyes with primary PD placement which required | |
| Repeat AM in the form of AMT | 4/24 (17) |
| Repeat AM in the form of PD | 6/24 (25) |
| Number of eyes which required more than two applications of AM | 6 (11) |
SJS = Stevens-Johnson syndrome; TEN = toxic epidermal necrolysis; IQR = inter-quartile range; AMT = amniotic membrane transplantation; PD = ProKera device; BCVA = best-corrected visual acuity
*
Grade of involvement was adapted from Sotozono et al.23